The cosmos is offering up a double feature in August: a pair of supermoons culminating in a rare blue moon.
Catch the first show Tuesday evening as the full moon rises in the southeast, appearing slightly brighter and bigger than normal. That’s because it will be closer than usual, just 222,159 miles (357,530 kilometers) away, thus the supermoon label.
The moon will be even closer the night of Aug. 30 — a scant 222,043 miles (357,344 kilometers) distant. Because it’s the second full moon in the same month, it will be what's called a blue moon.
“Warm summer nights are the ideal time to watch the full moon rise in the eastern sky within minutes of sunset. And it happens twice in August,” said retired NASA astrophysicist Fred Espenak, dubbed Mr. Eclipse for his eclipse-chasing expertise.
The last time two full supermoons graced the sky in the same month was in 2018. It won’t happen again until 2037, according to Italian astronomer Gianluca Masi, founder of the Virtual Telescope Project.
Masi will provide a live webcast of Tuesday evening’s supermoon, as it rises over the Coliseum in Rome.
“My plans are to capture the beauty of this ... hopefully bringing the emotion of the show to our viewers,” Masi said in an email.
“The supermoon offers us a great opportunity to look up and discover the sky,” he added.
This year’s first supermoon was in July. The fourth and last will be in September. The two in August will be closer than either of those.
Provided clear skies, binoculars or backyard telescopes can enhance the experience, Espenak said, revealing such features as lunar maria — the dark plains formed by ancient volcanic lava flows — and rays emanating from lunar craters.
According to the Old Farmer’s Almanac, the August full moon is traditionally known as the sturgeon moon. That’s because of the abundance of that fish in the Great Lakes in August, hundreds of years ago.
The sophisticated rocket sent a payload that included 24 satellites, a new, solar-powered space sail, and the ashes of 152 people, into space with its side boosters successfully returning to Earth unscathed.
That next step for meat alternatives will apparently include fish as companies like Wild Type, BlueNalu, and Finless Foods wager that, in the age of plant-based burgers, there’s room for seafood grown in the lab.
These are the headlines you Need 2 Know for Wednesday, June 19, 2019.
Elon Musk may be going to Vegas. The Las Vegas Convention and Visitors Authority has recommended that The Boring Company be chosen to construct a "people mover" below the expanding convention center.
Cannabis, hemp, reefer, marijuana, dope, pot, grass ー no matter what term you choose, they all refer to the same plant: cannabis sativa. It’s a common misconception that cannabis sativa exclusively means that particular strain of weed that makes you creative and focused (as opposed to indica, which promotes relaxation)ー but it’s actually the scientific name of the single plant that yields marijuana, CBD, and hemp, among other products.
These are the headlines you Need 2 Know for Tuesday, Feb. 19, 2019.
Canopy Growth CEO Bruce Linton won't guarantee investors dividends. What he will promise is a stake in global cannabis domination. "If people want a dividend, we are probably not the right stock. If they want some entity aimed at dominating a global opportunity that started in Canada, we are probably your best bet," Linton told Cheddar on Friday, one day after the company reported a massive spike in third-quarter revenue.
These are the headlines you Need 2 Know for Friday, Feb, 15, 2019.
It's a big week in cannabis earnings ー Aurora Cannabis reported Monday and Canopy Growth will report Thursday ー but Paul Rosen, CEO of cannabis private equity firm Tidal Royalty, said he's noticing a concerning trend."All the companies are facing gross margin compression because there are excise taxes, there's a massive marketing spend as we go to recreational cannabis, and there's also increased packaging costs. So I think you're going to see a trend line here, which is revenue and capacity going up, but gross margin is going down," Rosen told Cheddar Wednesday.
Opiant Pharmaceuticals, the developer of opioid antidote NARCAN, is in the process of developing a version of its lifesaving drug for cannabanoid overdoses, the company's CEO told Cheddar in an interview on Wednesday.
